ASP Isotopes (ASPI) Projected to Post Quarterly Earnings on Wednesday

Key Points

• ASP Isotopes will report quarterly results before the market opens on Wednesday, March 11, with analysts forecasting an EPS loss of ($0.1367) and revenue of $2.033 million for the quarter.
• The stock traded around $5.81 (mid-day) and has a market capitalization of $643.43 million, a negative P/E of -4.47, and a 12‑month range of $3.71–$14.49, reflecting recent volatility.
• Executives have been selling shares—CFO sold 80,000 and the COO sold 8,438—leaving insiders with 14.4% ownership, while analyst sentiment is mixed with an average rating of "Hold" and an average price target of $13.00.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) is expected to be issuing its results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.1367) per share and revenue of $2.0330 million for the quarter.

ASP Isotopes Price Performance

NASDAQ ASPI traded up $0.26 during mid-day trading on Monday, hitting $5.81. The stock had a trading volume of 5,052,732 shares, compared to its average volume of 5,251,898. The firm's 50 day moving average is $6.22 and its 200 day moving average is $7.68. The company has a debt-to-equity ratio of 1.04, a current ratio of 6.14 and a quick ratio of 6.10. The stock has a market capitalization of $643.43 million, a price-to-earnings ratio of -4.47 and a beta of 3.55. ASP Isotopes has a twelve month low of $3.71 and a twelve month high of $14.49.

Insider Buying and Selling at ASP Isotopes

In related news, CFO Heather Kiessling sold 80,000 shares of the company's stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $5.80, for a total value of $464,000.00. Following the transaction, the chief financial officer directly owned 732,500 shares in the company, valued at approximately $4,248,500. This represents a 9.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Robert Ainscow sold 8,438 shares of the firm's stock in a transaction on Friday, March 6th. The stock was sold at an average price of $5.44, for a total value of $45,902.72. Following the sale, the chief operating officer directly owned 1,537,817 shares of the company's stock, valued at approximately $8,365,724.48. This trade represents a 0.55% decrease in their position. The SEC filing for this sale provides additional information. 14.40% of the stock is owned by insiders.

Institutional Investors Weigh In On ASP Isotopes

A number of institutional investors have recently modified their holdings of the company. Alyeska Investment Group L.P. boosted its stake in shares of ASP Isotopes by 73.4% in the 4th quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company's stock valued at $26,191,000 after buying an additional 2,072,851 shares during the period. Marshall Wace LLP grew its position in shares of ASP Isotopes by 3,669.1% during the third quarter. Marshall Wace LLP now owns 1,279,121 shares of the company's stock worth $12,305,000 after buying an additional 1,245,184 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of ASP Isotopes by 37.9% during the third quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company's stock worth $43,451,000 after buying an additional 1,241,024 shares during the period. Jump Financial LLC purchased a new stake in shares of ASP Isotopes during the third quarter worth approximately $8,990,000. Finally, Squarepoint Ops LLC acquired a new stake in ASP Isotopes in the third quarter valued at approximately $6,011,000. 16.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on ASPI. Weiss Ratings reiterated a "sell (d-)" rating on shares of ASP Isotopes in a research report on Monday, December 29th. Cantor Fitzgerald assumed coverage on shares of ASP Isotopes in a research note on Thursday, December 4th. They set an "overweight" rating and a $13.00 price objective for the company. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $11.00 price objective on shares of ASP Isotopes in a report on Monday, November 24th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, ASP Isotopes presently has an average rating of "Hold" and an average target price of $13.00.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.